CHRNA7 and Alzheimer disease: Encenicline (EVP-6124 or MT-4666, FORUM Pharmaceuticals Inc., Watertown, MA, USA and Mitsubishi Tanabe Pharma, Osaka, Japan) is a selective partial agonist of α7nAChRs (Ki = 4.3 nM) and acts as a co-agonist with acetylcholine to enhance cognition; encenicline was in phase III clinical trials for AD treatment but was discontinued in 2015 due to gastrointestinal side effects [32].